Correlation between APRI, FIB-4 and GPR Indices to Fibroscan and HBeAg Status in Patients with Chronic Hepatitis B

Rina Erlina, Puspa Wardhani, Yessy Puspitasari, Ulfa Kholili

Abstract


Liver fibrosis is a complication of chronic hepatitis B. Early detection of liver fibrosis is important for therapy. The aspartate aminotransferase index (AST)-to-platelet ratio index (APRI) and the fibrosis index based on 4 factors (FIB-4) in chronic hepatitis B have been widely studied despite the inconsistent results. Research on other serum markers is extensively carried out, including Gamma-Glutamyl Transpeptidase (GGT)-to-platelet ratio (GPR). Previous studies have shown that the GPR index was more accurate than APRI and FIB-4. HBeAg status is an indication for therapy. There have not been many studies on the correlation of serum markers with HBeAg status. This study aimed to determine the correlation of APRI, FIB-4, and GPR with Fibroscan and HBeAg status in chronic hepatitis B patients. A cross-sectional study was carried out from June to September 2020 and found 50 chronic hepatitis B patients. Platelet count was measured using a Sysmex XN-1000 hematology device; AST, alanine aminotransferase (ALT), and GGT levels were measured using the Dimension RXL clinical chemistry device; and the degree of fibrosis was determined using transient elastography (Fibroscan). Spearman correlation test was used in this study for the correlation analysis. The results showed a significant correlation between APRI, FIB-4 and GPR indices with Fibroscan (r=0.454, p 0.001; r=0.610, p < 0.001; r=0.540, p < 0.001, respectively). A significant correlation was found between APRI, FIB-4 and GPR indices with negative (-) HBeAg (r=0.486, p 0.004; r=0.648, p < 0.001; r=0.595, p < 0.001, respectively). In addition, a significant correlation was found between FIB-4 and positive (+) HBeAg (r=0.499, p 0.049), but no correlation was found between APRI and GPR with positive (+) HBeAg (r=0.295, p 0,267; r=0.386, p 0.140, respectively).

Keywords


APRI, FIB 4, GPR, fibroscan, chronic hepatitis B, HBeAg

Full Text:

PDF

References


Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic

hepatitis B virus infection. Lancet, 2018; 392(10161):

-24.

Tang LSY, Covert E, Wilson E, Kottilil S. Chronic

hepatitis B infection a review. JAMA-J Am Med Assoc, 2018; 319(17): 1802-13.

Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer

H. Hepatology-a clinical textbook. 9th Ed., Germany,

Flying Publisher, 2018; 423.

Adrianti E, Kurniawan BL, A. Samad I. Comparisons of

fibro Q index and FIB-4 in various stages of chronic B

hepatitis. Indones J Clin Pathol Med Lab, 2018;

(1): 68.

Dimzova M, Kondova-Topuzovska I, Bosilkovski M,

Ivanovski L, Milenkovic Z, et al. Non-invasive

biomarkers in assessment of liver fibrosis in patients

with HBeag negative chronic hepatitis B. Open Access

Maced J Med Sci, 2018; 6(6): 1052-8.

Li Q, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of

APRI and FIB-4 for noninvasive assessment of

significant fibrosis and cirrhosis in HBeAg-negative

CHB patients with ALT?2 ULN A retrospective cohort

study. Med (United States), 2017; 96(12): 1-7.

Ruggieri A, Gagliardi MC, Anticoli S. Sex-dependent

outcome of hepatitis B and C Viruses infections:

Synergy of sex hormones and immune responses?.

Front Immunol, 2018; 9: 1-7.

Wang RQ, Zhang QS, Zhao SX, Niu XM, Du JH, et al.

Gamma-glutamyl transpeptidase to platelet ratio

index is a good non-invasive biomarker for predicting

liver fibrosis in Chinese chronic hepatitis B patients. J

Int Med Res, 2016; 44(6): 1302-13.

De Lédinghen V, Vergniol J. Transient elastography for

the diagnosis of liver fibrosis. Expert Rev Med Devices,

; 7(6): 811-23.

Li Q, Chen L, Zhou Y. Diagnostic accuracy of liver

stiffness measurement in chronic hepatitis B patients

with normal or mildly elevated alanine transaminase

levels. Sci Rep [Internet]. 2018; 8(1): 1-7. Available

from: http://dx.doi.org/10.1038/s41598-018-23646-2

(accessed at 5 June, 2020).

Liu D, Zhang Z, Wang Y, Ding R, Zhou X, et al.

Comparative evaluation of GPR versus APRI and FIB-4

in predicting different levels of liver fibrosis of chronic

hepatitis B. J Viral Hepatol, 2018; 25(5): 581-9.

Kim WR, Berg T, Asselah T, Flisiak R, Fung S, et al.

Evaluation of APRI and FIB-4 scoring systems for

non-invasive assessment of hepatic fibrosis in chronic

hepatitis B patients. J Hepatol [Internet]. 2015.

Available from: http://dx.doi.org/10.1016/

j.jhep.2015.11.012 (accessed at 5 June, 2020).

Bishop ML, Fody EP, Schoeff LE. Clinical chemistry

th -principles, techniques and correlations. 8 Ed.,

Philadelphia, Wolters Kluwer, 2018; 721-722.

Wu JP, Mao WL. Review of serum biomarkers and

models derived from them in HBV-related liver

diseases. Dis Markers, 2020; 2020.

Yang Y, Wang L, Yan L, Zhang L, Zhou W, et al. Platelet

count is closely associated with the severity of liver

injury in patients with chronic hepatitis B virus

infection: A cross-sectional study. Exp Ther Med, 2020;

(1): 243-50.

Wu JF, Chang MH. Natural history of chronic hepatitis

B virus infection from infancy to adult life-the

mechanism of inflammation triggering and long-term

impacts. J Biomed Sci, 2015; 22(1): 1-7.

Wang J, Yan X, Yang Y, Chang H, Jia B, et al. A novel

predictive model using routinely clinical parameters to

predict liver fibrosis in patients with chronic hepatitis

B. Oncotarget, 2017; 8(35): 59257-67.

Huang R, Wang G, Tian C, Liu Y, Jia B, et al.

Gamma-glutamyl-transpeptidase to platelet ratio is

not superior to APRI, FIB-4 and RPR for diagnosing

liver fibrosis in CHB patients in China. Sci Rep

[Internet]. 2017; 7(1): 1-10. Available from:

http://dx.doi.org/10.1038/s41598-017-09234-w

(accessed at 5 June, 2020).

Lee J, Kim MY, Kang SH, Kim J, Uh Y, et al. The

gamma-glutamyl transferase to platelet ratio and the

FIB-4 score are noninvasive markers to determine the

severity of liver fibrosis in chronic hepatitis B infection.

Br J Biomed Sci, 2018; 75(3): 128-32.

Hu YC, Liu H, Liu XY, Ma LN, Guan YH, et al. Value of

gamma-glutamyltranspeptidase-to-platelet ratio in

diagnosis of hepatic fibrosis in patients with chronic

hepatitis B. World J Gastroenterol, 2017; 23(41):

-32.

Ren T, Wang H, Wu R, Niu J. Gamma-glutamyl

transpeptidase-to-platelet ratio predicts significant

liver fibrosis of chronic hepatitis B patients in China.

Gastroenterol Res Pract, 2017; 1-7.

Lian MJ, Zhang JQ, Chen SD, Zhang DD, Yang YY, Hong

GL . D i agnos ti c a c c u r a c y of γ -gl u t a m y l

transpeptidase-to-platelet ratio for predicting

hepatitis B-related fibrosis: A meta-analysis. Eur J

Gastroenterol Hepatol, 2019; 31(5): 599-606.

EASL. EASL 2017 clinical practice guidelines on the

management of hepatitis B virus infection. J Hepatol,

; 67: 370-98.

Chen Y, Li Y, Li N, Fan X, Li C, et al. A non-invasive score

to predict liver fibrosis in HBeAg-positive hepatitis B

patients with normal or minimally elevated alanine

aminotransferase levels. Dis Markers, 2018; 2018.




DOI: http://dx.doi.org/10.24293/ijcpml.v27i3.1718

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.